

## DAFTAR PUSTAKA

- Adeloye, D., Song, P., Zhu, Y., Campbell, H., Rudan, I. 2022, Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis, *The Lancet Respiratory Medicine*, **10**(5), pp. 447–458. Available at: [https://doi.org/10.1016/S2213-2600\(21\)00511-7](https://doi.org/10.1016/S2213-2600(21)00511-7).
- Agustí, A., Melén, E., DeMeo, D. L., Breyer-Kohansal, R., Faner, R. 2022, Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene–environment interactions across the lifespan, *Lancet Respir Med*, **10**(5), pp. 512–524. Available at: [https://doi.org/10.1016/S2213-2600\(21\)00555-5](https://doi.org/10.1016/S2213-2600(21)00555-5).
- Ahn, J. H., Chung, J. H., Shin, K. C., Jin, H. J., Jong, G., Lee, M. S., dkk. 2020, The effects of repeated inhaler device handling education in COPD patients: a prospective cohort study, *Scientific Reports*, **10**(1). Available at: <https://doi.org/10.1038/s41598-020-76961-y>.
- Aldan, G., Helvacı, A., Ozdemir, L., Satar, S., Ergun, P. 2022, Multidimensional factors affecting medication adherence among patients with chronic obstructive pulmonary disease, *Journal of Clinical Nursing*, **31**(9–10), pp. 1202–1215. Available at: <https://doi.org/10.1111/jocn.15976>.
- Amini, S., Ghasemi, A., Solduzian, M., Rahimi, B., Heidari, K., Hadjibabaie, M., dkk. 2020, Is Inhaler Technique Associated with Quality of Life in Patients with Chronic Obstructive Pulmonary Disease?, *Current Therapeutic Research*, **93**, p. 100608. Available at: <https://doi.org/10.1016/j.curtheres.2020.100608>.
- Aziz, M. I. A., Tan, L. E., Wu, D. B. C., Pearce, F., Chua, G. S. W., Lin, L., dkk. 2018, Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: A systematic review and network meta-analysis, *International Journal of COPD*, **13**, pp. 3203–3231. Available at: <https://doi.org/10.2147/COPD.S173472>.
- Badan Penelitian dan Pengembangan Kesehatan. 2013, *Riset Kesehatan Dasar*, Jakarta, Kementerian Kesehatan Republik Indonesia.
- Bagherisadeghi, G., Larhrib, E. H. dan Chrystyn, H. 2017, Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort® Turbuhaler®, *International Journal of Pharmaceutics*, **522**(1–2), pp. 137–146. Available at: <https://doi.org/10.1016/j.ijpharm.2017.02.057>.
- Basheti, I. A., Qunaibi, E., Bosnic-Anticevich, S. Z., Armour, C. L., Khater, S., Omar, M., Reddel, H. K. 2011, User error with diskus and turbuhaler by asthma patients and pharmacists in Jordan and Australia, *Respiratory Care*, **56**(12), pp. 1916–1923. Available at: <https://doi.org/10.4187/respcare.01205>.

- Beeh, K. M., Derom, E., Echave-Sustaeta, J., Grönke, L., Hamilton, A., Zhai, D., dkk. 2016, The lung function profile of once-daily tiotropium and olodaterol via respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via a accuhaler® (Energito® study), *International Journal of COPD*, **11**, pp. 193–205. Available at: <https://doi.org/10.2147/COPD.S95055>.
- Bhattarai, B., Walpola, R., Mey, A., Anoopkumar-Dukie, S., Khan, S. 2020, Barriers and strategies for improving medication adherence among people living with copd: A systematic review, *Respiratory Care*, **65**(11), pp. 1738–1750. Available at: <https://doi.org/10.4187/respcare.07355>.
- Blair, H. A. 2019, Tiotropium/Olodaterol: A Review in COPD, *Drugs*, **79**(9), pp. 997–1008. Available at: <https://doi.org/10.1007/s40265-019-01133-w>.
- Boateng, G. O., Neilands, T. B., Frongillo, E. A., Melgar-Quiñonez, H. R., Young, S. L. 2018, Best Practices for Developing and Validating Scales for Health, Social, and Behavioral Research: A Primer, *Frontiers in Public Health*, **6**, 149. Available at: <https://doi.org/10.3389/fpubh.2018.00149>.
- Bollmeier, S. G. dan Hartmann, A. P. 2020, Management of chronic obstructive pulmonary disease: A review focusing on exacerbations, *American Journal of Health-System Pharmacy*, **77**(4), pp. 259–268. Available at: <https://doi.org/10.1093/ajhp/zxz306>.
- Brennan, V., Mulvey, C. dan Costello, R. W. 2021, The clinical impact of adherence to therapy in airways disease, *Breathe*, **17**:210039. Available at: <https://doi.org/10.1183/20734735.0039-2021>.
- Buhl, R., Dreher, M., Mattiucci-Guehlke, M., Emerson-Stadler, R., Eckhardt, S., Taube, C., dkk. 2023, EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS, *Advances in Therapy*, **40**(7), pp. 3263–3278. Available at: <https://doi.org/10.1007/s12325-023-02524-y>.
- Cadth, 2015, *CDR clinical review report for Inspiroto Respimat (tiotropium bromide monohydrate and olodaterol hydrochloride)*. Canadian Agency for Drugs and Technologies in Health.
- Calzetta, L., Di Marco, F., Blasi, F., Cazzola, M., Centanni, S., Micheletto, C., dkk. 2019, Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis, *Pulmonary Pharmacology and Therapeutics*, **59**. Available at: <https://doi.org/10.1016/j.pupt.2019.101855>.
- Celli, B., Fabbri, L., Criner, G., Martinez, F. J., Mannino, D., Vogelmeier, C., dkk. 2022, Definition and nomenclature of chronic obstructive pulmonary disease time for its revision, *Am J Respir Crit Care Med*, **206**(11), pp. 1317–1325. Available at: <https://doi.org/10.1164/rccm.202204-0671PP>.

- Celli, B. R., Fabbri, L. M., Aaron, S. D., Agusti, A., Brook, R., Criner, G. J., dkk. 2021, An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The rome proposal, *Am J Respir Crit Care Med*, **204**(11), pp. 1251–1258. Available at: <https://doi.org/10.1164/rccm.202108-1819PP>.
- Chen, C. Y., Pan, S. W., Hsu, C. C., Liu, J. J., Kumamaru, H., Dong, Y. H. 2023, Comparative cardiovascular safety of LABA/LAMA FDC versus LABA/ICS FDC in patients with chronic obstructive pulmonary disease: a population-based cohort study with a target trial emulation framework, *Respiratory Research*, **24**(1). Available at: <https://doi.org/10.1186/s12931-023-02545-9>.
- Chen, S., Kuhn, M., Prettnner, K., Yu, F., Yang, T., Bärnighausen, T., dkk. 2023, The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020-50: a health-augmented macroeconomic modelling study, *The Lancet Global Health*, **11**(8), pp. e1183- e1193. Available at: [www.thelancet.com/lancetgh](http://www.thelancet.com/lancetgh).
- Chen, Z., Zhu, C., Cui, Z., Zou, F., Lan, Y. 2026, Safety Assessment of Budesonide/Formoterol: Real-World Pharmacovigilance Analysis Using the FAERS, JADER, and CVAR Databases, *Clinical Therapeutics*, S0149-2918(25)00423-0. Available at: <https://doi.org/10.1016/j.clinthera.2025.12.013>.
- Cheng, S. L., Lin, C. H., Wang, C. C., Chan, M. C., Hsu, J. Y., Hang, L. W., dkk. 2019, Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients, *J Formos Med Assoc*, **118**(1P3), pp. 429–435. Available at: <https://doi.org/10.1016/j.jfma.2018.06.018>.
- Cheng, S. L. 2021, Comparison of effectiveness using different dual bronchodilator agents in chronic obstructive pulmonary disease treatment, *Journal of Clinical Medicine*, **10**(12). Available at: <https://doi.org/10.3390/jcm10122649>.
- Cheng, S. L. dan Lin, C. H. 2016, Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts, *International Journal of COPD*, **11**(1), pp. 2341–2348. Available at: <https://doi.org/10.2147/COPD.S115132>.
- Cheng, W., Duan, J., Zhou, A., Zhao, Y., Yi, R., Liu, Y., dkk. 2021, Real-world effectiveness of inhalation therapy among patients with symptomatic COPD in China: A multicenter prospective study, *Front Pharmacol*, **12**. Available at: <https://doi.org/10.3389/fphar.2021.753653>.
- Covert, K., Brooks, S. dan Burchette, J. E. 2025, Novel Maintenance Therapies for Chronic Obstructive Pulmonary Disorder, *Annals of Pharmacotherapy*, 10600280251382202 Available at: <https://doi.org/10.1177/10600280251382202>.

- Dalimunthe, R. A. dan Arbaningsih, S. R. 2020, Hubungan antara COPD Assessment Test (CAT) dengan faal paru pada pasien penyakit paru obstruktif kronis di Rumah Sakit Dr. Pirngadi Medan Tahun 2018, *Jurnal Pandu Husada*, **2**(1), pp. 122–129. Available at: <https://doi.org/10.30596/jph.v1i2.4575>.
- Dekhuijzen, P. N. R., Lavorini, F. Dan Usmani, O.S. 2016, Patients' perspectives and preferences in the choice of inhalers: The case for Respimat® or HandiHaler®, *Patient Preference and Adherence*, **10**, pp. 1561–1572. Available at: <https://doi.org/10.2147/PPA.S82857>.
- Deneuve, O. M., Pradana, A. dan Tarigan, A. P. 2024<sup>a</sup>, The Relationship Between ICS LABA Administration and Blood Eosinophil Levels in COPD Patient at USU General Hospital, *Journal of Society Medicine*, **3**(12), pp. 374–378. Available at: <https://doi.org/10.47353/jsocmed.v3i12.180>.
- Deneuve, O. M., Pradana, A. dan Tarigan, A. P. 2024<sup>b</sup>, The relationship of blood eosinophils levels with degree of exacerbation in COPD patient at USU General Hospital, *Journal of Society Medicine*, **3**(7), pp. 217–222. Available at: <https://doi.org/10.47353/jsocmed.v3i7.155>.
- Derom, E., Brusselle, G. G. dan Joos, G. F. 2016, Efficacy of tiotropium–olodaterol fixed-dose combination in COPD, *International Journal of COPD*, **11**(1), pp. 3163–3177. Available at: <https://doi.org/10.2147/COPD.S92840>.
- Dhar, R., Talwar, D., James, P., Mishra, A., Vachaparambil, J., Patil, S., dkk. 2022, ICS/Ultra LABA in the Treatment of Obstructive Airway Diseases: A Consensus of Indian Experts, *Advances in Respiratory Medicine*, **90**(5), pp. 407–424. Available at: <https://doi.org/10.3390/arm90050051>.
- Dinas Kesehatan Daerah Istimewa Yogyakarta (DIY). 2017, *Daftar Rumah Sakit yang Bekerjasama dengan BPJS Kesehatan di DIY*. Diakses pada 13 Juli 2025. <https://dinkes.jogjapro.go.id/berita/detail/rumah-sakit-kerjasama-bpjs-daftar-rumah-sakit-yang-bekerjasama-dengan-bjps-kesehatan-di-diy>.
- Ding, B., Small, M. dan Holmgren, U. 2017, A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications, *International Journal of COPD*, **12**, pp. 1527–1537. Available at: <https://doi.org/10.2147/COPD.S133793>.
- D'Urzo, A., Donohue, J. F., Kardos, P., Miravittles, M., Price, D. 2015, A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease, *Expert Opinion on Pharmacotherapy*, **16**(12), pp. 1845–1860. Available at: <https://doi.org/10.1517/14656566.2015.1067682>.

- Farkas, Á., Jókay, Á., Balásházy, I., Füri, P., Müller, V., Tomisa, G., dkk. 2016, Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort® Turbuhaler® dry powder fixed combination aerosol drug, *European Journal of Pharmaceutical Sciences*, **93**, pp. 371–379. Available at: <https://doi.org/10.1016/j.ejps.2016.08.036>.
- Ferguson, G. T., Maltais, F., Karpel, J., Bothner, U., Kloer, I., Trampisch, M., dkk. 2020, Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies, *NPJ Prim Care Respir Med*, **30**(1). Available at: <https://doi.org/10.1038/s41533-020-00212-w>.
- Fukuda, N., Horita, N., Kaneko, A., Goto, A., Kaneko, T., Ota, E., dkk. 2023, Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease,” *Cochrane Database of Systematic Reviews*, **2023**(6). Available at: <https://doi.org/10.1002/14651858.CD012066.pub3>.
- García-Sidro, P., Naval, E., Martínez Rivera, C., Bonnin-Vilaplana, M., Garcia-Rivero, J. L., Herrejón, A., dkk. 2015, The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations, *Respiratory Medicine*, **109**(12), pp. 1546–1552. Available at: <https://doi.org/10.1016/j.rmed.2015.10.011>.
- Garin, O. 2014, ‘Ceiling Effect’, in A. C. Michalos (ed.), *Encyclopedia of Quality of Life and Well-Being Research*, Dordrecht: Springer Netherlands, pp. 631–633. Available at: [https://doi.org/10.1007/978-94-007-0753-5\\_296](https://doi.org/10.1007/978-94-007-0753-5_296).
- Gil, H. I., Zo, S., Jones, P. W., Kim, B. G., Kang, N., Choi, Y., dkk. 2021, Clinical characteristics of COPD patients according to COPD assessment test (CAT) score level: Cross-sectional study, *International Journal of COPD*, **16**, pp. 1509–1517. Available at: <https://doi.org/10.2147/COPD.S297089>.
- Global Burden of Disease (GBD). 2021, *Chronic Obstructive Pulmonary Disease - Level 3 Cause*, Institute for Health Metrics and Evaluation. Available at: [www.thelancet.com](http://www.thelancet.com).
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2025, *Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2025 Report*, Tersedia di: <https://goldcopd.org/>.
- Gold, D. T. dan McClung, B. 2006, Approaches to patient education: Emphasizing the long-term value of compliance and persistence, *Am J Med*, **119**(4 SUPPL. 1), pp. S32–S37. Available at: <https://doi.org/10.1016/j.amjmed.2005.12.021>.
- Gültürk, E. A. 2024, Scale adaptation and redevelopment: A review on validity and reliability, *J Cell Mol Immunol*, **3**(1), pp. 26-32. Available at: <https://doi.org/10.46439/immunol.3.027>.

- EL Hajjar, S. T. 2018, Statistical Analysis: Internal-Consistency Reliability and Construct Validity, *International Journal of Quantitative and Qualitative Research Methods*, **6**(1), pp. 46–57. Available at: [www.eajournals.org](http://www.eajournals.org).
- Hanan, N. D., Windari, N. I. dan Fathurrahman, M. H. 2026, Gambaran Kepatuhan Pasien Penyakit Paru Obstruktif Kronik (PPOK) Dalam Penggunaan Terapi Inhaler di Instalasi Rawat Jalan RSD Dr. A. Dadi Tjokrodipo (RSDADT) Bandar Lampung, *Jurnal Farmasi Udayana*, **14**, pp.51-57. Available at: <https://doi.org/10.24843/JFU.2025.v14.i02.p01>.
- Harb, H. S., Laz, N. I., Rabea, H., Abdelrahim, M. E. A. 2021, Determinants of incorrect inhaler technique in chronic obstructive pulmonary disease patients, *Int J Clin Pract*, **75**(6), e14073. Available at: <https://doi.org/10.1111/ijcp.14073>.
- Herdman, M., Fox-Rushby, J. dan Badia, X. 1998, A model of equivalence in the cultural adaptation of HRQoL instruments: the universalist approach, *Quality of Life Research*, **7**(4), p. 323. Available at: <https://doi.org/https://doi.org/10.1023/a:1024985930536>.
- Hernández Alberola, A., Bartolomé Nogal, N., Blanco Miranda, A., Lipson, D. A., Tombs, L., Han, M. K. 2024, The Effect of Patient Sex on Treatment Outcomes in COPD: A Post Hoc Analysis of the IMPACT Trial, *Chronic Obstr Pulm Dis*, **11**(6), pp. 591–603. Available at: <https://doi.org/10.15326/jcopdf.2024.0541>.
- Hizawa, N. 2015, LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes, *International Journal of COPD*, **10**, pp. 1093–1102. Available at: <https://doi.org/10.2147/COPD.S72858>.
- Hodder, R., Reese, P. R. dan Slaton, T. 2009, International Journal of COPD Dovepress Asthma patients prefer respimat® soft Mist TM Inhaler to Turbuhaler®, *International Journal of COPD*, **4**, pp. 225-232. Available at: <https://www.dovepress.com/>.
- Homętowska, H., Świątoniowska-Lonc, N., Klekowski, J., Chabowski, M., Jankowska-Polańska, B. 2022, Treatment Adherence in Patients with Obstructive Pulmonary Diseases, *International Journal of Environmental Research and Public Health*, **19**(18). Available at: <https://doi.org/10.3390/ijerph191811573>.
- Hozawa, S., Terada, M. dan Hozawa, M. 2011, Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma, *Pulmonary Pharmacology and Therapeutics*, **24**(5), pp. 571–576. Available at: <https://doi.org/10.1016/j.pupt.2011.05.004>.

- Huang, W. C., Chen, C. Y., Liao, W. C., Wu, B. R., Chen, W. C., Tu, C. Y., dkk. 2022, Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD, *Journal of Clinical Medicine*, **11**(23). Available at: <https://doi.org/10.3390/jcm11237165>.
- Hughes, R., Rapsomaniki, E., Janson, C., Keen, C., Make, B. J., Burgel, P. R., dkk. 2022, Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study, *Respiratory Medicine*, **200**. Available at: <https://doi.org/10.1016/j.rmed.2022.106921>.
- Ilmi, T., Sari, T. P., Probosiwi, N., Laili, N. F. 2023, Evaluasi Rasionalitas Pemakaian Obat dan Hasil Terapi pada Pasien Paru Obstruktif Kronik (PPOK) Rawat Jalan Di RSUD X, Kraksaan, *Jurnal Inovasi Farmasi Indonesia (JAFI)*, **5**(1), pp. 19–29. Available at: <https://doi.org/10.30737/jafi.v5i1.5084>.
- Iwanaga, T., Tohda, Y., Nakamura, S., Suga, Y. 2019, The Respimat® Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients, *Clinical Drug Investigation*, **39**(11), pp. 1021–1030. Available at: <https://doi.org/10.1007/s40261-019-00835-z>.
- Izquierdo-Condoy, J. S., Gualpa Álvarez, F., Morales-Lapo, E., Arias Calvache, W. D., Bermúdez Moreira, J., Quinga-Chiguano, K. M., dkk. 2025, Adherence to inhalation therapy among COPD patients: A cross-sectional study in a tertiary hospital in Quito, Ecuador, *Int J Chron Obstruct Pulm Dis*, **20**, pp. 399–410. Available at: <https://doi.org/10.2147/COPD.S493992>.
- Jailaini, M. F. M., Muneswarao, J., Hao, C. Z., Hussain, R., Hamid, M. F. A. 2024, Inhaler personalisation based on peak inspiratory flow (PIF) among dry powder inhaler users: a pilot randomised control trial (RCT) in COPD, *Journal of Pharmaceutical Policy and Practice*, **17**(1). Available at: <https://doi.org/10.1080/20523211.2024.2415425>.
- Jang, J. G., Chung, J. H., Shin, K. C., Jin, H. J., Lee, K. H., Ahn, J. H. 2021, Comparative study of inhaler device handling technique and risk factors for critical inhaler errors in Korean COPD patients, *Int J Chron Obstruct Pulmon Dis*, **16**, pp. 1051–1059. Available at: <https://doi.org/10.2147/COPD.S303761>.
- Janson, C. 2020, Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease, *Journal of Thoracic Disease*, **12**(4), pp. 1561–1569. Available at: <https://doi.org/10.21037/jtd.2020.02.51>.
- Jo, Y. S., Yoon, H. I., Kim, D. K., Yoo, C. G., Lee, C. H. 2018, Comparison of COPD assessment test and clinical COPD questionnaire to predict the risk of exacerbation, *International Journal of COPD*, **13**, pp. 101–107. Available at: <https://doi.org/10.2147/COPD.S149805>.

- Karloh, M., Mayer, A. F., Maurici, R., Pizzichini, M. M. M., Jones, P. W., Pizzichini, E. 2016, The COPD assessment test: What do we know so far? A systematic review and meta-analysis about clinical outcomes prediction and classification of patients into gold stages, *Chest*, **149**(2), pp. 413–425. Available at: <https://doi.org/10.1378/chest.15-1752>.
- Karloh, M., Rocha, S. A. V., Pizzichini, M. M. M., Cavalli, F., Matte, D. L., Pizzichini, E. 2018, Is the COPD Assessment Test sensitive for differentiating COPD patients from active smokers and nonsmokers without lung function impairment? a population-based study, *J Bras Pneumol*, **44**(3), pp. 213–219. Available at: <https://doi.org/10.1590/s1806-37562017000000149>.
- Kementerian Kesehatan Republik Indonesia. 2023, *Formularium Nasional*, Jakarta, Kementerian Kesehatan Republik Indonesia.
- Kerkhof, M., Voorham, J., Dorinsky, P., Cabrera, C., Darken, P., Kocks, J. W. H., dkk. 2020, Association between COPD exacerbations and lung function decline during maintenance therapy, *Thorax*, **75**(9), pp. 744–753. Available at: <https://doi.org/10.1136/thoraxjnl-2019-214457>.
- Kharbanda, S. dan Anand, R. 2021, Health-related quality of life in patients with chronic obstructive pulmonary disease: A hospital-based study, *Indian J Med Res*, **153**(4), pp. 459–464. Available at: [https://doi.org/10.4103/ijmr.IJMR\\_1812\\_18](https://doi.org/10.4103/ijmr.IJMR_1812_18).
- Koarai, A., Sugiura, H., Yamada, M., Ichikawa, T., Fujino, N., Kawayama, T., dkk. 2020, Treatment with LABA versus LAMA for stable COPD: A systematic review and meta-analysis, *BMC Pulmonary Medicine*, **20**(10). Available at: <https://doi.org/10.1186/s12890-020-1152-8>.
- Kon, S. S. C., Canavan, J. L., Jones, S. E., Nolan, C. M., Clark, A. L., Dickson, M. J., dkk. 2014, Minimum clinically important difference for the COPD Assessment Test: A prospective analysis, *The Lancet Respiratory Medicine*, **2**(3), pp. 195–203. Available at: [https://doi.org/10.1016/S2213-2600\(14\)70001-3](https://doi.org/10.1016/S2213-2600(14)70001-3).
- Koo, T. K. dan Li, M. Y. 2016, A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research, *Journal of Chiropractic Medicine*, **15**(2), pp. 155–163. Available at: <https://doi.org/10.1016/j.jcm.2016.02.012>.
- Kostikas, K., Greulich, T., Mackay, A. J., Lossi, N. S., Aalamian-Mattheis, M., Nunez, X., dkk. 2019, Treatment response in COPD: Does FEV1 say it all? a post hoc analysis of the CRYSTAL study, *ERJ Open Res*, **5**(1). Available at: <https://doi.org/10.1183/23120541.00243-2018>.
- Kugler, S., Nagy, A., Kerekes, A., Veres, M., Rigó, I., Czitrovsky, A. 2019, Determination of emitted particle characteristics and upper airway deposition of Symbicort® Turbuhaler® dry powder inhaler, *Journal of Drug Delivery Science and Technology*, **54**. Available at: <https://doi.org/10.1016/j.jddst.2019.101229>.

- Kwon, N., Amin, M., Hui, d. S., Jung, K. S., Lim, S. Y., Ta, H. D., dkk. 2013, Validity of the COPD Assessment Test translated into local languages for Asian patients, *Chest*, **143**(3), pp. 703–710. Available at: <https://doi.org/10.1378/chest.12-0535>.
- Lai, Y. T., Tsai, Y. H., Hsieh, M. J., Chen, N. H., Cheng, S. L., Tao, C. W., dkk. 2024, Benefit of dual bronchodilator therapy on exacerbations in former and current smokers with chronic obstructive pulmonary disease in real-world clinical practice: a multicenter validation study (TOReTO), *Respiratory Research*, **25**(1). Available at: <https://doi.org/10.1186/s12931-024-02971-3>.
- Lemeshow, S., Hosmen Jr., D. W., Klar, J., Lwanga, S. K. 1990, *Adequacy of Sample Size in Health Studies*, England: World Health Organization by John Wiley & Sons Ltd.
- Li, X., Song, Q., Cheng, W., Liu, C., Li, L., Peng, Y., dkk. 2023, The clinical characteristics and outcomes of different inhaled therapies in chronic obstructive pulmonary disease patients with frequent cough, *Annals of Medicine*, **55**(2). Available at: <https://doi.org/10.1080/07853890.2024.2304107>.
- Liang, Y. R., Chang, C. H., Huang, S. Y., Wu, Y. K., Yang, M. C., Huang, K. L., dkk. 2025, Comparative Analysis of ICS Combined with LABA versus Addition of Omalizumab on Transcriptomic Expression Profiles in Patients with Allergic Asthma, *Journal of Asthma and Allergy*, **18**, pp. 941–954. Available at: <https://doi.org/10.2147/JAA.S511885>.
- Lin, L., Song, Q., Cheng, W., Liu, C., Zhao, Y. Y., Duan, J. X., dkk. 2022, Comparison of predictive value of CAT and change in CAT in the short term for future exacerbation of chronic obstructive pulmonary disease, *Ann Med*, **54**(1), pp. 875–885. Available at: <https://doi.org/10.1080/07853890.2022.2055134>.
- Liu, Y. R., Wang, Y., Wang, J., dan Wang, X. 2024, Association between illness perception and adherence to inhaler therapy in elderly Chinese patients with chronic obstructive pulmonary disease, *Chronic Respiratory Disease*, **21**. Available at: <https://doi.org/10.1177/14799731241286837>.
- López-Campos, J. L., Gallego, E. Q. dan Hernández, L. C. 2019, Status of and strategies for improving adherence to copd treatment, *International Journal of COPD*, **14**, pp. 1503–1515. Available at: <https://doi.org/10.2147/COPD.S170848>.
- Lorensia, A., Puspitasari, M. D., Soedarsono, S., dan Suryadinata, R. V. 2022, Cost-Effectiveness Analysis of Budesonide/Formoterol and Fluticasone/Salmeterol for Stable Chronic Obstructive Lung Disease, *Jurnal Respirologi Indonesia*, **42**(4). Available at: <https://doi.org/10.36497/jri.v42i4.378>.

- Luley, M. C., Loleit, T., Knopf, e., Djukic, M., Criée, C. P., dan Nau, R. 2020, Training improves the handling of inhaler devices and reduces the severity of symptoms in geriatric patients suffering from chronic-obstructive pulmonary disease, *BMC Geriatrics*, **20**(1). Available at: <https://doi.org/10.1186/s12877-020-01804-4>.
- Luo, J., Zhang, D., Tang, W., Dou, L. Y., dan Sun, Y. 2021, Impact of frailty on the risk of exacerbations and all-cause mortality in elderly patients with stable chronic obstructive pulmonary disease, *Clin Interv Aging*, **16**, pp. 593–601. Available at: <https://doi.org/10.2147/CIA.S303852>.
- Ma, J., Sun, X., Wang, X., Liu, B., dan Shi, K. 2023, Factors Affecting Patient Adherence to Inhalation Therapy: An Application of SEIPS Model 2.0, *Patient Preference and Adherence*, **17**, pp. 531–545. Available at: <https://doi.org/10.2147/PPA.S395327>.
- Mackay, A. J., Donaldson, G. C., Patel, A. R. C., Jones, P. W., Hurst, J. R., dan Wedzicha, J. A. 2012, Usefulness of the chronic obstructive pulmonary disease assessment test to evaluate severity of COPD exacerbations, *American Journal of Respiratory and Critical Care Medicine*, **185**(11), pp. 1218–1224. Available at: <https://doi.org/10.1164/rccm.201110-1843OC>.
- MacLeod, M., Papi, A., Contoli, M., Beghé, B., Celli, B. R., Wedzicha, J., dkk. 2021, Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact, *Respirology*, **26**(6), pp. 532–551. Available at: <https://doi.org/10.1111/resp.14041>.
- Malerba, M., Foci, V., Patrucco, F., Pochetti, P., Nardin M., Pelaia, C., dkk. 2019, Single inhaler LABA/LAMA for COPD, *Frontiers in Pharmacology*, **10**(APR). Available at: <https://doi.org/10.3389/fphar.2019.00390>.
- Mara, Y. A., Ikawati, Z. dan Pramantara, I. D. P. 2023, *Pengaruh Penggunaan Flutikason/Salmeterol Dibandingkan Budesonid/Formoterol Terhadap Kejadian Pneumonia Pada Pasien Penyakit Paru Obstruktif Kronis di RSUP Dr. Sardjito Yogyakarta*, Fakultas Farmasi, Universitas Gadjah Mada, Yogyakarta.
- Maricoto, T., Santos, D., Carvalho, C., Teles, I., Correia-de-Sousa, J., dan Taborda-Barata, L. 2020, Assessment of Poor Inhaler Technique in Older Patients with Asthma or COPD: A Predictive Tool for Clinical Risk and Inhaler Performance, *Drugs and Aging*, **37**(8), pp. 605–616. Available at: <https://doi.org/10.1007/s40266-020-00779-6>.
- Martinez, C. H., Murray, S., Barr, R. G., Blecker, E., Bowler, R. P., Christenson, S. A., dkk. 2017, Respiratory symptoms items from the COPD assessment test identify ever-smokers with preserved lung function at higher risk for poor respiratory outcomes an analysis of the subpopulations and intermediate outcome measures in COPD Study cohort, *Annals of the American Thoracic Society*, **14**(5), pp. 636–642. Available at: <https://doi.org/10.1513/AnnalsATS.201610-815OC>.

- Matera, M. G., Cardaci, V., Cazzola, M., dan Rogliani, P. 2015, Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease, *Expert Opinion on Drug Safety*, **14**(4), pp. 533–541. Available at: <https://doi.org/10.1517/14740338.2015.1001363>.
- Matera, M. G., Calzetta, L., Puxeddu, E., Rogliani, P., dan Cazzola, M. 2018, A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD, *Expert Opinion on Drug Safety*, **17**(5), pp. 509–517. Available at: <https://doi.org/10.1080/14740338.2018.1448786>.
- Matera, M. G., Hanania, N. A., Maniscalco, M., dan Cazzola, M. 2023, Pharmacotherapies in older adults with COPD: Challenges and opportunities, *Drugs Aging*, **40**(7), pp. 605–619. Available at: <https://doi.org/10.1007/s40266-023-01038-0>.
- Melani, A. S., Croce, S., Fabbri, G., Messina, M., dan Bargagli, E. 2024, Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History, *Biomolecules*, **14**(2). Available at: <https://doi.org/10.3390/biom14020195>.
- Miravittles, M., Auladell-Rispau, A., Monteagudo, M., Vázquez-Niebla, J. C., Mohammed, J., Nuñez, A., dkk. 2021, Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD, *European Respiratory Review*, **30**(160). European Respiratory Society. Available at: <https://doi.org/10.1183/16000617.0075-2021>.
- Miravittles, M., Kawayama, T. dan Dreher, M. 2022, LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations, *Journal of Clinical Medicine*, **11**(22). Available at: <https://doi.org/10.3390/jcm11226623>.
- Miyazaki, M., Nakamura, H., Chubachi, S., Sasaki, M., Haraguchi, M., Yoshida, S., dkk. 2014, Analysis of comorbid factors that increase the COPD assessment test scores, *Respir Res*, **15**(13). Available at: <http://respiratory-research.com/content/15/1/13>.
- Molimard, M., Raheison, C., Lignot, S., Balestra, A., Lamarqua, S., Chartier, A., dkk. 2017, Chronic obstructive pulmonary disease exacerbation and inhaler device handling: Real-life assessment of 2935 patients, *European Respiratory Journal*, **49**(2). Available at: <https://doi.org/10.1183/13993003.01794-2016>.
- Mollica, M., Aronne, L., Paoli, G., Flora, M., Mazzeo, G., Tartaglione, S., dkk. 2021, Elderly with COPD: Comorbidity and systemic consequences, *Journal of Gerontology and Geriatrics*, **69**(1), pp. 32–44. Available at: <https://doi.org/10.36150/2499-6564-434>.
- Monteagudo, M., Nuñez, A., Barrecheguren, M., dan Miravittles, M. 2022, Effectiveness of treatment with dual bronchodilation (LABA/LAMA) compared with combination therapy (LABA/ICS) for patients with COPD: A population-based study, *Arch Bronconeumol*, **58**(10), pp. 699–707. Available at: <https://doi.org/10.1016/j.arbres.2022.05.002>.

- Monteiro, C., Maricoto, T., Prazeres, F., Augusto Simões, P., dan Augusto Simões, J. 2022, Determining factors associated with inhaled therapy adherence on asthma and COPD: A systematic review and meta-analysis of the global literature, *Respiratory Medicine*, **191**. Available at: <https://doi.org/10.1016/j.rmed.2021.106724>.
- de Moreira, A. T. A., Pinto, C. R., Lemos, A. C. M., Assunção-Costa, L., Souza, G., dan Netto, E. M. 2022, Evidence of the association between adherence to treatment and mortality among patients with COPD monitored at a public disease management program in Brazil, *J Bras Pneumol*, **48**(1). Available at: <https://doi.org/10.36416/1806-3756/e20210120>.
- Murillo, E. R., Mora, J. R. M., Bachiller, M. M., Santiago, L. G., Braqué, N. N., dan Bravo, M. 2025, Factors associated with low adherence to inhaled therapy in patients with chronic respiratory diseases: a cross-sectional study, *BMC Pulmonary Medicine*, **25**(1). Available at: <https://doi.org/10.1186/s12890-025-03563-7>.
- Nash, D. 2021, Poor Inhaler Adherence and Techniques – How Can We Improve It?, *Current Geriatrics Reports*, **10**, pp. 66–71. Available at: <https://doi.org/10.1007/s13670-021-00355-9/Published>.
- Newton, R. dan Giembycz, M. A. 2016, Understanding how long-acting  $\beta$ 2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma – an update, *British Journal of Pharmacology*, **173**(24), pp. 3405–3430. Available at: <https://doi.org/10.1111/bph.13628>.
- Pandey, A. K., Verma, A. K., Singh, A., Kant, S., Chaudhary, S. C., Bajpai, J., dan Dixit, R. K. 2024, The severity of non-smoking chronic obstructive pulmonary disease is correlated with biomass fuel exposure and COPD assessment test score, *Lung India*, **41**(4), pp. 251–258. Available at: [https://doi.org/10.4103/lungindia.lungindia\\_304\\_23](https://doi.org/10.4103/lungindia.lungindia_304_23).
- Papaioannou, M., Pitsiou, G., Manika, K., Kontou, P., Zarogoulidis, P., Sichletidis, L., dkk. 2014, COPD Assessment Test: A simple tool to evaluate disease severity and response to treatment, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **11**(5), pp. 489–495. Available at: <https://doi.org/10.3109/15412555.2014.898034>.
- Pei, H., Su, Y., Jing, G., Su, Q., Xu, J., Jin, X., dkk. 2026, Patterns and Adherence to GOLD-Recommended Inhaled Therapy in Chronic Obstructive Pulmonary Disease (COPD) Patients with Acute Exacerbation History in Primary Care in China, *International Journal of Chronic Obstructive Pulmonary Disease*, **21**, pp. 1–14. Available at: <https://doi.org/10.2147/COPD.S566724>.
- Perhimpunan Dokter Paru Indonesia. 2023, *Penyakit Paru Obstruktif Kronik (PPOK) Pedoman Diagnosis dan Penatalaksanaan di Indonesia*. Jakarta: Perhimpunan Dokter Paru Indonesia.

- Perneger, T. V., Courvoisier, D. S., Hudelson, P. M., dan Gayet-Ageron, A. 2015, Sample size for pre-tests of questionnaires, *Quality of Life Research*, **24**(1), pp. 147–151. Available at: <https://doi.org/10.1007/s11136-014-0752-2>.
- Petite, S. E. 2017, Role of Long-Acting Muscarinic Antagonist/Long-Acting  $\beta$ 2-Agonist Therapy in Chronic Obstructive Pulmonary Disease, *Annals of Pharmacotherapy*, **51**(8), pp. 696–705. Available at: <https://doi.org/10.1177/1060028017705149>.
- Pisi, R., Aiello, M., Calzetta, L., Frizzeli, A., Tzani, P., Bertorelli, G., dan Chetta, A. 2023, The COPD assessment test and the modified Medical Research Council scale are not equivalent when related to the maximal exercise capacity in COPD patients, *Pulmonology*, **29**(3), pp. 194–199. Available at: <https://doi.org/10.1016/j.pulmoe.2021.06.001>.
- Pitcairn, G., Reader, S., Pavia, D., dan Newman, S. 2005, Deposition of Corticosteroid Aerosol in the Human Lung by Respimat® Soft Mist™ Inhaler Compared to Deposition by Metered Dose Inhaler or by Turbuhaler® Dry Powder Inhaler, *Journal of Aerosol Medicine*, **18**(3), pp. 264–272. Available at: <https://doi.org/10.1089/jam.2005.18.264>.
- Plaza, V., Fernández-Rodríguez, C., Melero, C., Cosío, B. G., Entrenas, L. M., De Llano, L. P., dkk. 2016, Validation of the ‘Test of the Adherence to Inhalers’ (TAI) for asthma and COPD patients, *J Aerosol Med Pulm Drug Deliv*, **29**(2), pp. 142–152. Available at: <https://doi.org/10.1089/jamp.2015.1212>.
- Plaza, V., Giner, J., Curto, E., Alonso-Ortiz, M. B., Orue, M. I., Vega, J. M., dkk. 2021, Assessing adherence by combining the test of adherence to inhalers with pharmacy refill records, *Journal of Investigational Allergology and Clinical Immunology*, **31**(1), pp. 58–64. Available at: <https://doi.org/10.18176/jiaci.0461>.
- Plaza, V., López-Viña, A. dan Cosío, B.G. 2017, Test of Adherence to Inhalers, *Archivos de Bronconeumología*, **53**(7), pp. 360–361. Available at: <https://doi.org/10.1016/j.arbr.2017.03.005>.
- Quint, J. K., Montonen, J., Esposito, D. B., He, X., Koerner, L., Wallace, L., dkk. 2021, Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database, *Advances in Therapy*, **38**(5), pp. 2249–2270. Available at: <https://doi.org/10.1007/s12325-021-01646-5>.
- Rabe, K. F., Fernando, J., Ferguson, G. T., Wang, C., Singh, D., Wedzicha, J. A., dkk. 2020, Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD, *N Engl J Med*, **383**(1), pp. 35–48. Available at: <https://doi.org/10.1056/nejmoa1916046>.

- Ram, F. S. F., Carvallho, C. R. dan White, J. 2011, Clinical effectiveness of the respimat® inhaler device in managing chronic obstructive pulmonary disease: Evidence when compared with other handheld inhaler devices, *International Journal of COPD*, **6**(1), pp. 129–139. Available at: <https://doi.org/10.2147/COPD.S8092>.
- Ramadan, W. H., Kabbara, W. K., El Khoury, G. M., dan Al Assir, S. A. 2015, Combined bronchodilators (Tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease, *International Journal of COPD*, **10**(1), pp. 2347–2356. Available at: <https://doi.org/10.2147/COPD.S88246>.
- Ramírez-Venegas, A., Montiel-Lopez, F., Robles-Hernández, R. E., Celli, B. R., Sansores, R. H., Cassou-Martínez, M., dkk. 2024, Effectiveness of ICS/LABA and LAMA/LABA in COPD due to biomass, *ERJ Open Res*, **10**(6), pp. 00154–02024. Tersedia di: <https://doi.org/10.1183/23120541.00154-2024>.
- Rawat, G. dan Chandra, A. 2024, Evaluation of the treatment satisfaction and medication adherence among chronic pulmonary obstructive diseases patients-a cross sectional study, *Library Progress International*, **44**(3), pp. 7559–7575. Tersedia di: <https://bpasjournals.com/library-science/index.php/journal/article/view/1834>.
- Rigby, D. 2024, Inhaler device selection for people with asthma or chronic obstructive pulmonary disease, *Australian Prescriber*, **47**(5), pp. 140–147. Tersedia di: <https://doi.org/10.18773/austprescr.2024.046>.
- Roche, N., Aggarwal, B., Boucot, I., Mittal, K., Martin, A., dan Chrystyn, H. 2022, The impact of inhaler technique on clinical outcomes in adolescents and adults with asthma: A systematic review, *Respiratory Medicine*, **202**, pp. 106949. Tersedia di: <https://doi.org/10.1016/j.rmed.2022.106949>.
- Rodrigo, G. J., Price, D., Anzueto, A., Singh, D., Altman, P., Bader, G., dkk. 2017, LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: A systematic review and meta-analysis, *International Journal of COPD*, **12**, pp. 907–922. Tersedia di: <https://doi.org/10.2147/COPD.S130482>.
- Rumah Sakit Bethesda. 2025, *Visi & Misi Rumah Sakit Bethesda*. Tersedia di: <https://www.bethesda.or.id/visi-&ampamp-misi.html> (Diakses 12 Maret 2025).
- Sanduzzi, A., Balbo, P., Candoli, P., Catapano, G. A., Contoni, P., Mattei, A., dkk. 2014, COPD: Adherence to therapy, *Multidisciplinary Respiratory Medicine*, **9**(1), pp. 60. Tersedia di: <https://doi.org/10.1186/2049-6958-9-60>.
- dos Santos, N.C., Miravittles, M., Camelier, A. A., de Almeida, V. D. C., Maciel, R. R. B. T., dan Camelier, F. 2022, Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review, *Tuberculosis and Respiratory Diseases*, **85**(3), pp. 205–220. Tersedia di: <https://doi.org/10.4046/trd.2021.0179>.

- Sari, C. P., Hanifah, S., Rosdiana, R., dan Anisa, Y. 2020, The COPD (chronic obstructive pulmonary disease) assessment test: Assessment of therapeutic outcomes of patients at private hospitals in Yogyakarta, *Journal of Pharmacy and Bioallied Sciences*, **12**(6), pp. S821–S825. Tersedia di: [https://doi.org/10.4103/jpbs.JPBS\\_302\\_19](https://doi.org/10.4103/jpbs.JPBS_302_19).
- Sari, C. P., Hanifah, S., Rosdiana, R., dan Anisa, Y. 2021, Efektivitas Pengobatan pada Pasien Penyakit Paru Obstruksi Kronis (PPOK) di Rumah Sakit Wilayah Yogyakarta, *Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, **11**(4), p. 215. Tersedia di: <https://doi.org/10.22146/jmpf.56418>.
- Sauriasari, R., Madani, R. A., Rozaliyani, A., dan Sudiana, D. 2021, The effect of repeated education using live demonstrations and videos of how to use inhalation drugs on quality of life for COPD patients, *Heliyon*, **7**(9), p. e07870. Tersedia di: <https://doi.org/https://doi.org/10.1016/j.heliyon.2021.e07870>.
- Shin, H. J., Kim, Y. I., Kim, Y., Lee, C. Y., Ra, S. W., Moon, J. Y., dkk. 2023, When is LABA/LAMA better than LAMA in GOLD group B or D patients for reducing acute exacerbations of COPD?, *Chonnam Med J*, **59**(3), p. 180. Tersedia di: <https://doi.org/10.4068/cmj.2023.59.3.180>.
- Singarimbun, M. dan Effendi, S. 2011, *Metode Penelitian Survei*, LP3ES, Jakarta.
- Streiner, D. L., Norman, G. R. dan Cairney, J. 2024, *Health Measurement Scales*, Oxford University Press. Tersedia di: <https://doi.org/10.1093/med/9780192869487.001.0001>.
- Sugiyono. 2013, *Metode penelitian pendidikan: Pendekatan kuantitatif, kualitatif dan R & D*, Alfabeta, Bandung.
- Suissa, S., Dell’Aniello, S. dan Ernst, P. 2019, Comparative effectiveness and safety of LABA-LAMA vs LABA-ICS treatment of COPD in real-world clinical practice, *Chest*, **155**(6), pp. 1158–1165. Tersedia di: <https://doi.org/10.1016/j.chest.2019.03.005>.
- Suissa, S., Dell’Aniello, S. dan Ernst, P. 2021, Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety, *Respiratory Medicine*, **189**, p. 106645. Tersedia di: <https://doi.org/https://doi.org/10.1016/j.rmed.2021.106645>.
- Taber, K. S. 2018, The Use of Cronbach’s Alpha When Developing and Reporting Research Instruments in Science Education, *Research in Science Education*, **48**(6), pp. 1273–1296. Tersedia di: <https://doi.org/10.1007/s11165-016-9602-2>.
- Tanabe, N. dkk. (2026) “Identifying high-risk smokers without airflow limitation using new COPD criteria: pooled analysis of two Japanese cohorts,” *Respiratory Investigation*, **64**(2). Tersedia di: <https://doi.org/10.1016/j.resinv.2026.101368>.

- Tashkin, D. P., Ohar, J. A., Koltun, A., Alan, R., dan Ward, J. K. 2021, The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device, *Pulmonary Medicine*, pp. 1-7. Tersedia di: <https://doi.org/10.1155/2021/8881895>.
- Taylor, T. H. 2010, *Ceiling Effect*, Encyclopedia of Research Design, United States: SAGE Publications, Inc., pp. 133–134. Tersedia di: <https://doi.org/10.4135/9781412961288.n44>.
- Thomashow, B., Stiegler, M., Criner, G. J., Dransfield, M. T., Halpin, D. M. G., Han, M. L. K., dkk. 2022, Higher COPD Assessment Test Score Associated with Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial, *Chronic Obstructive Pulmonary Diseases*, **9**(1), pp. 68–79. Tersedia di: <https://doi.org/10.15326/JCOPDF.2021.0259>.
- Turégano-Yedro, M., Trillo-Calvo, E., Navarro I Ros, F., Maya-Viejo, J. D., González Villaescusa, C., Echave Sustaeta, J. M., dkk. 2023, Inhaler Adherence in COPD: A Crucial Step Towards the Correct Treatment, *International Journal of COPD*, **18**, pp. 2887–2893. Tersedia di: <https://doi.org/10.2147/COPD.S431829>.
- Usmani, O. S., Hickey, A. J., Guranlioglu, D., Rawson, K., Stjepanovic, N., Siddiqui, S., dkk. 2021, The Impact of Inhaler Device Regimen in Patients with Asthma or COPD, *The Journal of Allergy and Clinical Immunology: In Practice*, **9**(8), pp. 3033-3040.e1. Tersedia di: <https://doi.org/https://doi.org/10.1016/j.jaip.2021.04.024>.
- Valderas, J. M., Starfield, B. Sibbald, B., Salisbury, C., dan Roland, M. 2009, Defining comorbidity: Implications for understanding health and health services, *Ann Fam Med*, **7**(4), pp. 357–363. Tersedia di: <https://doi.org/10.1370/afm.983>.
- Valladales-Restrepo, L. F., Oyuela-Gutiérrez, M. C., Delgado-Araujo, A. C., Calvo-Salazar, J., Osorio-Bustamante, D., Lerma-Barco, C. E., dkk. 2023, Adherence to Inhalation Devices in Patients with Chronic Obstructive Pulmonary Disease, *Patient Preference and Adherence*, **17**, pp. 3233–3244. Tersedia di: <https://doi.org/10.2147/PPA.S432808>.
- Vanoverschelde, A., Van Der Wel, P., Putman, B., dan Lahousse, L. 2021, Determinants of poor inhaler technique and poor therapy adherence in obstructive lung diseases: A cross-sectional study in community pharmacies, *BMJ Open Respiratory Research*, **8**(1). Tersedia di: <https://doi.org/10.1136/bmjresp-2020-000823>.
- Varol, Y., Ozacar, R., Balci, G., Usta, L., dan Taymaz, Z. 2014, Assessing the effectiveness of the COPD Assessment Test (CAT) to evaluate COPD severity and exacerbation rates, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **11**(2), pp. 221–225. Tersedia di: <https://doi.org/10.3109/15412555.2013.836169>.

- Varol, Y., Anar, C., Çimen, P., Ünlü, M., Halilçolar, H., dan Güçlü, S. 2017, Sex-related differences in COPD assessment test scores of COPD populations with or without significant anxiety and/or depression, *Turkish Journal of Medical Sciences*, **47**(1), pp. 61–68. Tersedia di: <https://doi.org/10.3906/sag-1509-60>.
- Vedel-Krogh, S., Nordestgaard, B. G., Lange, P., Vestbo, J., dan Nielsen, S. F. 2018, Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD, *Eur Respir J*, **51**(5). Tersedia di: <https://doi.org/10.1183/13993003.00120-2018>.
- Vestbo, J., Anderson, J. A., Calverley, P. M. A., Celli, B., Ferguson, G. T., Jenkins, C., dkk. 2009, Adherence to inhaled therapy, mortality and hospital admission in COPD, *Thorax*, **64**(11), pp. 939–943. Tersedia di: <https://doi.org/10.1136/thx.2009.113662>.
- Vogelmeier, C. F., Bateman, E. D., Pallante, J., Alagappan, V. K. T., D’Andrea, P., Chem, H., dkk. 2013, Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): A randomised, double-blind, parallel group study, *Lancet Respir Med*, **1**(1), pp. 51–60. Tersedia di: [https://doi.org/10.1016/S2213-2600\(12\)70052-8](https://doi.org/10.1016/S2213-2600(12)70052-8).
- Vogelmeier, C. F., Román-Rodríguez, M., Singh, D., Han, M. K., Rodríguez-Roisin, R., dan Ferguson, G. T. 2020, Goals of COPD treatment: Focus on symptoms and exacerbations, *Respiratory Medicine*, **166**, p. 105938. Tersedia di: <https://doi.org/10.1016/j.rmed.2020.105938>.
- AL Wachami, N., Guennouni, M., Iderdar, Y., Boumendil, K., Arraji, M., Mourajid, Y., dkk. 2024, Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): a systematic review and meta-analysis, *BMC Public Health*, **24**(1). Tersedia di: <https://doi.org/10.1186/s12889-024-17686-9>.
- Wedzicha, J. A., Banerji, D., Chapman, K. R., Vestbo, J., Roche, N., Ayers, R. T., dkk. 2016, Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD, *N Engl J Med*, **374**(23), pp. 2222–2234. Tersedia di: <https://doi.org/10.1056/nejmoa1516385>.
- Weiss, A., Porter, S., Rozenberg, D., O’Connor, E., Lee, T., Balter, M., dkk. 2020, Chronic Obstructive Pulmonary Disease: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions, *Journal of Pain and Symptom Management*, **60**(1), pp. 135–150. Tersedia di: <https://doi.org/10.1016/j.jpainsymman.2020.01.009>.
- Westerik, J. A. M., Metting, E. I., van Boven, J. F. M., Tiersma, W., Kocks, J. W. H. Dan Schermer, T. R. 2017, Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD, *Respir Res*, **18**(1). Tersedia di: <https://doi.org/10.1186/s12931-017-0512-2>.

- World Health Organization. 2025, 'Indonesia', *WHO Data*, viewed 2 Maret 2025, <https://data.who.int/countries/360>.
- Wulandari, A. dan Veryanti, P. R. 2020, Analisis Biaya Terapi Pasien Penyakit Paru Obstruktif Kronik (PPOK) Rawat Inap di RSUP Fatmawati Periode 2018, *Sainstech Farma: Jurnal Ilmu Kefarmasian*, **13**(1), pp. 8–4. Tersedia di: <https://doi.org/https://doi.org/10.37277/sfj.v13i1.517>.
- Yamada, H., Hida, N. dan Hizawa, N. 2018, Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting  $\beta$ 2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan, *Int J Chron Obstruct Pulmon Dis*, **13**, pp. 3141–3147. Tersedia di: <https://doi.org/10.2147/COPD.S179285>.
- Zhang, W., Xu, L., Gao, S., Ding, N., Shu, P., Wang, Z., dkk. 2020, Technical evaluation of soft mist inhaler use in patients with chronic obstructive pulmonary disease: A cross-sectional study, *International Journal of COPD*, **15**, pp. 1471–1479. Tersedia di: <https://doi.org/10.2147/COPD.S253338>.
- Zhong, N., Wang, C., Zhou, X., Zhang, N., Humphries, M., Wang, L., dkk. 2015, LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD, *Int J Chron Obstruct Pulmon Dis*, **10**, pp. 1015–1026. Tersedia di: <https://doi.org/10.2147/COPD.S84436>.